Authors’ Reply to Comment on “Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide”

The Original Article was published on 12 February 2020

A Therapy in Practice to this article was published on 21 September 2019

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Bahat G, Ilhan B, Karan MA. Comment on “Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide”. Drugs Aging. 2020. https://doi.org/10.1007/s40266-020-00751-4.

    Article  PubMed  Google Scholar 

  2. 2.

    Raterman HG, Lems WF. Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide. Drugs Aging. 2019;36(12):1061–72. https://doi.org/10.1007/s40266-019-00714-4.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018;379(26):2547–56. https://doi.org/10.1056/NEJMcp1800214.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hennie G. Raterman.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflicts of interest

Hennie G. Raterman has received an unrestricted educational grant from UCB, and consulting fees from Amgen, Cellgene and Sanof Genzyme. Willem F. Lems has received a grant from Pfzer, and consulting fees from MSD, Amgen, Lilly, Pfzer and UCB.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Raterman, H.G., Lems, W.F. Authors’ Reply to Comment on “Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide”. Drugs Aging 37, 239–240 (2020). https://doi.org/10.1007/s40266-020-00751-4

Download citation